A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
Latest Information Update: 27 Mar 2024
At a glance
- Drugs Dupilumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms LIBERTY AD ADOL
- Sponsors Regeneron Pharmaceuticals
- 26 Feb 2024 Results of pooled analysis of LIBERTY AD PRESCHOOL,LIBERTY AD PEDS , LIBERTYAD ADOL , LIBERTY AD SOLO1,LIBERTYADSOLO2 reporting serum CCL17/TARC (human TARC Quantikine ELISA kit; R&D Systems) levels from patients with moderate-to-severe or severe AD, presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 27 Feb 2023 Results assessing type 2 and general inflammatory biomarker serum levels from patients from studies (NCT03346434; part B, NCT03345914 & NCT03054428) were presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 27 Feb 2023 Results of pooled analysis (from 6 phase 3 studies (NCT03346434, NCT03345914, NCT03054428, NCT02260986, NCT02277743 and NCT02277769) assessing IgE levels in patients aged 6 months and older with moderate-to-severe AD presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology